Acne Annihilation: Dermata's XYNGARI™ Shatters Phase 3 Goals, Heralding a New Era in Skin Treatment!

Dermata Therapeutics' XYNGARI™ achieves highly statistically significant results in its Phase 3 STAR-1 trial for moderate-to-severe acne, meeting all three co-primary endpoints^{2, 8}.
Remarkable efficacy seen early: XYNGARI™ showed significant improvement over placebo after just four weekly treatments³.
The company is well-funded into Q1 2026, paving the way for the crucial second Phase 3 trial (STAR-2) and further development.

San Diego, CA – The fight against acne has a powerful new contender. Dermata Therapeutics (NASDAQ:DRMA, DRMAW) today unveiled a corporate update that sent ripples of excitement through the dermatological world, headlined by the phenomenal success of its XYNGARI™ Phase 3 STAR-1 trial. This isn't just progress; it's a potential paradigm shift.

"It was an electrifying quarter," declared Gerry Proehl, Dermata's Chairman, President, and CEO. "Witnessing XYNGARI™ deliver such positive topline results, decisively achieving statistical significance across all three co-primary endpoints at every time point, validates the years of dedication our team has poured into this groundbreaking product." At week 12, a striking 29.4% of XYNGARI™ patients achieved clear or almost clear skin, nearly double the 15.2% in the placebo group ((p < 0.001))^{2, 8}.

The data paints a compelling picture: XYNGARI™, a novel, once-weekly, natural topical treatment, demonstrated not only profound efficacy but also a rapid onset of action. Statistically significant separation from placebo was observed after a mere four weeks³. This resounding victory significantly de-risks the upcoming second Phase 3 trial (STAR-2) and positions XYNGARI™ to potentially become the first once-weekly, natural, topical champion for moderate-to-severe acne, if approved⁵.

But Dermata's vision extends beyond acne. "We're also thrilled to collaborate with Revance, exploring DMT410 – leveraging our XYNGARI™ technology – with DAXXIFY® for the topical treatment of axillary hyperhidrosis," Proehl added. This Phase 2 study could unlock new frontiers for needle-free delivery of botulinum toxins¹.

With manufacturing for the STAR-2 trial underway and initiation planned by year-end 2025, plus discussions for partnerships buzzing, Dermata is charging forward. Bolstered by $9.7 million in cash as of March 31, 2025, the company is robustly funded into early 2026 to pursue these transformative goals. The future of skincare is looking clearer, and Dermata is leading the charge. For more information, visit Dermata Therapeutics.

Acne Annihilation: Dermata's XYNGARI™ Shatters Phase 3 Goals, Heralding a New Era in Skin Treatment!

References

Stay Updated!